OBJECTIVE: Although chest CT is the primary tool for evaluating bronchiectasis, accurately measuring its extent poses challenges. This study aimed to automatically quantify bronchiectasis using an artificial intelligence (AI)-based analysis of the bronchial tapering ratio on chest CT and assess its association with clinical outcomes in patients with chronic obstructive pulmonary disease (COPD).
MATERIALS AND METHODS: COPD patients from two prospective multicenter cohorts were included. AI-based airway quantification was performed on baseline CT, measuring the tapering ratio for each bronchus in the whole lung. The bronchiectasis score accounting for the extent of bronchi with abnormal tapering (inner lumen tapering ratio ≥ 1.1, indicating airway dilatation) in the whole lung was calculated. Associations between the bronchiectasis score and all-cause mortality and acute exacerbation (AE) were assessed using multivariable models.
RESULTS: The discovery and validation cohorts included 361 (mean age, 67 years; 97.5% men) and 112 patients (mean age, 67 years; 93.7% men), respectively. In the discovery cohort, 220 (60.9%) had a history of at least one AE and 59 (16.3%) died during follow-up, and 18 (16.1%) died in the validation cohort. Bronchiectasis score was independently associated with increased mortality (discovery: adjusted HR, 1.86 [95% CI: 1.08-3.18]; validation: HR, 5.42 [95% CI: 1.97-14.92]). The score was also associated with risk of any AE, severe AE, and shorter time to first AE (for all, p
* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.